ERBB3 and cancer: Indeed, a number of HER3-targeted mAbs and Ab-drug conjugates (ADCs) have been reported to exert potent antitumor activity in preclinical studies of various cancer types and some of them show promising results in clinical evaluations [26, 30, 33, 34].